Recommendations for the use of parenteral methotrexate in rheumatic diseases

被引：9

作者：

Tornero Molina, Jesus ^{[1
]}

Calvo Alen, Jaime ^{[2
]}

Ballina, Javier ^{[3
]}

Angeles Belmonte, Maria ^{[4
]}

Blanco, Francisco J. ^{[5
]}

Angel Caracuel, Miguel ^{[6
]}

Carbonell, Jordi ^{[7
]}

Corominas, Hector ^{[8
]}

Chamizo, Eugenio ^{[9
]}

Hidalgo, Cristina ^{[10
]}

Roman Ivorra, Jose ^{[11
]}

Luis Marenco, Jose ^{[12
]}

Moreno Muelas, Jose Vicente ^{[13
]}

Munoz-Fernandez, Santiago ^{[14
]}

Nolla, Joan M. ^{[15
]}

Perez, Trinidad ^{[16
]}

Sanmarti, Raimon ^{[17
]}

Trenor, Pilar ^{[18
]}

Urrego, Claudia ^{[19
]}

Vidal, Javier ^{[1
]}

Gomez de Salazar, Jose Rosas ^{[20
]}

机构：

[1] Hosp Guadalajara, Serv Reumatol, Guadalajara, Spain

[2] Hosp Univ Araba, Vitoria, Spain

[3] Hosp Univ Cent Asturias, Oviedo, Spain

[4] Hosp Reg Univ Malaga, Malaga, Spain

[5] CHUAC, La Coruna, Spain

[6] Hosp Univ Reina Sofia, Cordoba, Spain

[7] Hosp del Mar, Barcelona, Spain

[8] Hosp St Joan Despi Moises Broggi, Barcelona, Spain

[9] Hosp Merida, Badajoz, Spain

[10] Complejo Asistencial Univ Salamanca, Salamanca, Spain

[11] Hosp Univ & Politecn La Fe, Valencia, Spain

[12] Hosp Virgen de Valme, Seville, Spain

[13] Hosp Univ Vall dHebron, Barcelona, Spain

[14] Univ Europea Madrid, Hosp Univ Infanta Sofia, Madrid, Spain

[15] Hosp Univ Bellvitge, Barcelona, Spain

[16] Hosp Leon, Leon, Spain

[17] Hosp Univ Clin, Barcelona, Spain

[18] Hosp Clin Valencia, Valencia, Spain

[19] Complejo Asistencial Segovia, ,, Segovia, Spain

[20] Hosp Marina Alta de la Villajoyosa, Alicante, Spain

来源：

REUMATOLOGIA CLINICA | 2018年 / 14卷 / 03期

关键词：

Methotrexate; Parenteral; Rheumatic diseases;

D O I：

10.1016/j.reuma.2016.12.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To develop recommendations for the use of parenteral methotrexate (MTX) in rheumatic diseases, mainly rheumatoid arthritis, based on best evidence and experience.& para;& para;Methods: A group of 21 experts on parenteral MTX use was selected. The coordinator formulated 13 questions about parenteral MTX (indications, efficacy, safety and cost-effectiveness). A systematic review was conducted to answer the questions. Using this information, inclusion and exclusion criteria were established, as were the search strategies (involving Medline, EMBASE and the Cochrane Library). Three different reviewers selected the articles. Evidence tables were created. Abstracts from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) were evaluated. Based on this evidence, the coordinator proposed preliminary recommendations that the experts discussed and voted in a nominal group meeting. The level of evidence and grade of recommendation were established using the Oxford Center for Evidence-Based Medicine and the level of agreement with the Delphi technique (2 rounds). Agreement was established if at least 80% of the experts voted yes (yes/no).& para;& para;Results: Most of the evidence involved rheumatoid arthritis. A total of 13 preliminary recommendations on the use of parenteral MTX were proposed; 11 of them were accepted. Two of the 13 were not voted and are commented on in the main text.& para;& para;Conclusions: The manuscript aims to solve frequent questions and help in decision-making strategies when treating patients with parenteral MTX. (C) 2016 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.

引用

页码：142 / 149

页数：8

共 50 条

[21] Austrian Recommendations for the Use of Methotrexate in Rheumatic Disorders Focusing on Rheumatoid Arthritis
Haindl, P. M.
Rintelen, B.
Brezinschek, H. P.
Herold, M.
Eberl, G.
Wolf, J.
Machold, K.
Nothnagl, T.
Leeb, B. F.
AKTUELLE RHEUMATOLOGIE, 2010, 35 (04) : 251 - 259
[22] The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases
Furst, DE
BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (11): : 1196 - 1204
[23] HEPATOTOXICITY OF METHOTREXATE IN RHEUMATIC DISEASES
KEVAT, S
AHERN, M
HALL, P
MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1988, 3 (03): : 197 - 208
[24] Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis
Todoerti, M.
Maglione, W.
Bernero, E.
Bortoluzzi, A.
Colaci, M.
Galuppi, E.
Paolino, S.
Talarico, R.
Cutolo, M.
Ferri, C.
Trotta, F.
Bombardieri, S.
Montecucco, C. Maurizio
Sinigaglia, L.
REUMATISMO, 2013, 65 (05) : 207 - 218
[25] Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases
AlEnizi, Ahmad
AlSaeid, Khaled
Alawadhi, Adel
Hasan, Eiman
Husain, Entesar H.
AlFadhli, Ahmad
Ghanem, Aqeel
Abutiban, Fatemah
Ali, Yaser
Al-Herz, Adeeba
Mohammed, Khuloud
Alkandari, Waleed
Aldei, Ali
Alhajeri, Hebah
Dehrab, Ahmad
Hayat, Sawsan
INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2018, 2018
[26] Current "off label use" of Methotrexate for chronic inflammatory rheumatic diseases
Briem, S.
Lorenz, H. -M.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2011, 70 (02): : 123 - +
[27] CONSENSUS RECOMMENDATIONS ON THE USE OF BIOSIMILARS IN THE TREATMENT OF INFLAMMATORY RHEUMATIC JOINT DISEASES
Alnaqbi, K.
Al Adhoubi, N.
Al Dallal, S.
Al Emadi, S.
Al-Herz, A.
El Shamy, A.
Hannawi, S.
Omair, M. A.
Saad, S.
Kvien, T. K.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 2025 - 2026
[28] Significant mortality benefit with prolonged use of methotrexate in patients with rheumatic diseases.
Hyrich, KL
ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S574 - S574
[29] COMBINATION METHOTREXATE AND SULFASALAZINE IN THE TREATMENT OF RHEUMATIC DISEASES
SHIROKY, JB
NEVILLE, C
BALLACHEY, ML
ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S268 - S268
[30] Homocysteine and inflammatory rheumatic diseases on therapy with methotrexate
Wagener, P
Hein, R
Blum, W
AKTUELLE RHEUMATOLOGIE, 2002, 27 (01) : 29 - 32

← 1 2 3 4 5 →